235 related articles for article (PubMed ID: 12756509)
1. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
Kowalski J; Okopień B; Madej A; Zieliński M; Belowski D; Kalina Z; Herman ZS
Eur J Clin Pharmacol; 2003 Jul; 59(3):189-93. PubMed ID: 12756509
[TBL] [Abstract][Full Text] [Related]
2. Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia.
Kowalski J; Okopien B; Madej A; Zielinski M; Belowski D; Kalina Z; Herman ZS
Int J Clin Pharmacol Ther; 2003 Jun; 41(6):241-7. PubMed ID: 12816176
[TBL] [Abstract][Full Text] [Related]
3. Monocyte suppressing action of fenofibrate.
Okopień B; Kowalski J; Krysiak R; Łabuzek K; Stachura-Kułach A; Kułach A; Zieliński M; Herman ZS
Pharmacol Rep; 2005; 57(3):367-72. PubMed ID: 15985720
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Milionis HJ; Papakostas J; Kakafika A; Chasiotis G; Seferiadis K; Elisaf MS
J Clin Pharmacol; 2003 Aug; 43(8):825-30. PubMed ID: 12953339
[TBL] [Abstract][Full Text] [Related]
5. Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.
Okopien B; Huzarska M; Kulach A; Stachura-Kulach A; Madej A; Belowski D; Zielinski M; Herman ZS
J Cardiovasc Pharmacol; 2005 Feb; 45(2):160-4. PubMed ID: 15654265
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome.
Xu ZM; Zhao SP; Li QZ; Nie S; Zhou HN
Clin Chim Acta; 2003 Dec; 338(1-2):17-24. PubMed ID: 14637261
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Krysiak R; Gdula-Dymek A; Marek B; Okopień B
Endokrynol Pol; 2015; 66(3):224-30. PubMed ID: 26136131
[TBL] [Abstract][Full Text] [Related]
8. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.
Okopien B; Krysiak R; Haberka M; Herman ZS
J Cardiovasc Pharmacol; 2005 Apr; 45(4):314-20. PubMed ID: 15772519
[TBL] [Abstract][Full Text] [Related]
9. Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidemic subjects.
Marketou ME; Zacharis EA; Nikitovic D; Ganotakis ES; Parthenakis FI; Maliaraki N; Vardas PE
Angiology; 2006; 57(2):211-8. PubMed ID: 16518530
[TBL] [Abstract][Full Text] [Related]
10. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
Milionis HJ; Kakafika AI; Tsouli SG; Athyros VG; Bairaktari ET; Seferiadis KI; Elisaf MS
Am Heart J; 2004 Oct; 148(4):635-40. PubMed ID: 15459594
[TBL] [Abstract][Full Text] [Related]
11. Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats.
Vukšić A; Lovrić J; Konjevoda P; Blažević N; Bilušić M; Bradamante V
Arh Hig Rada Toksikol; 2019 Mar; 70(1):30-35. PubMed ID: 30956215
[TBL] [Abstract][Full Text] [Related]
12. Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
Lampl Y; Lorberboym M; Gilad R; Vysberg I; Tikozky A; Sadeh M; Boaz M
Clin Neuropharmacol; 2010 May; 33(3):129-34. PubMed ID: 20502132
[TBL] [Abstract][Full Text] [Related]
13. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
[TBL] [Abstract][Full Text] [Related]
14. Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.
Melenovsky V; Wichterle D; Simek J; Malik J; Haas T; Ceska R; Malik M
Am J Cardiol; 2003 Aug; 92(3):337-41. PubMed ID: 12888150
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Broncel M; Bała A; Koter-Michalak M; Duchnowicz P; Wojsznis W; Chojnowska-Jezierska J
Wiad Lek; 2007; 60(7-8):321-8. PubMed ID: 18175550
[TBL] [Abstract][Full Text] [Related]
18. The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
Krysiak R; Gdula-Dymek A; Marek B; Okopień B
Endokrynol Pol; 2016; 67(2):190-6. PubMed ID: 26884290
[TBL] [Abstract][Full Text] [Related]
19. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin.
Grip O; Janciauskiene S; Lindgren S
Inflamm Bowel Dis; 2004 May; 10(3):193-200. PubMed ID: 15290911
[TBL] [Abstract][Full Text] [Related]
20. PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.
Ceska R; Stulc T; Zima T; Malbohan I; Fialova L
Atherosclerosis; 2003 Jan; 166(1):195-6. PubMed ID: 12482567
[No Abstract] [Full Text] [Related]
[Next] [New Search]
